PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) was founded in 2013 and is headquartered in Cranbury, New Jersey, USA, with 39 full-time employees. It is a precision oncology company dedicated to discovering and developing small molecules targeting p53 mutations, and then discovering and Develop treatments for unknown tumors.
PMV Pharmaceuticals (PMVP):
PMV Pharma is developing first-in-class p53 modulators for the treatment of cancer. PMV Pharma brings together leaders in the field to leverage more than three decades of p53 biology, combining a unique biological understanding with a focus on drug development.
p53 is a well-defined tumor suppressor protein, known as the “guardian of the genome”, while normal or native p53 has the ability to eliminate cancer cells. However, the mutant p53 protein may misfold and lose its native tumor suppressor function. These p53 mutations account for about half of all cancers.
The field of p53 biology was established by Dr. Arnold Levine, the co-founder of PMV Pharma, when he discovered the p53 protein in 1979. PMV Pharma uses more than 40 years of research experience and has unique insights into p53 to create a precise oncology platform that aims to generate selective, small-molecule, unknown tumor therapies to correct specific structures The mutant p53 protein to restore its native function.
PMV Pharma is deploying our precision oncology platform to target the top 10 most common or hotspot p53 mutations, which are commonly associated with approximately 10% to 15% of all cancers.
PMV Pharma has designed the candidate product PC14586 to effectively and selectively correct the p53 misfolding caused by the specific p53 mutation Y220C, while retaining wild-type p53. The Y220C mutation is associated with 1.0% to 1.5% of all cancers, including breast cancer, non-small cell lung cancer or NSCLC, colorectal cancer, pancreatic cancer and ovarian cancer.
PMV Pharmaceuticals (PMVP) financing:
- On December 2, 2014, in Series A financing, PMV Pharmaceuticals received a lead investment from OrbiMed, followed by a US$30 million investment from InterWest Partners and OUP (Osage University Partners).
- On February 22, 2017, in Series B financing, PMV Pharmaceuticals received a lead investment from Topspin Partners, followed by Euclidean Capital, OrbiMed, InterWest Partners and OUP (Osage University Partners) with a total of $74 million in funding.
- On November 13, 2019, in Series C financing, PMV Pharmaceuticals received a lead investment of Nextech Invest, and 7 institutions including Viking Global Investors, OrbiMed, InterWest Partners, OUP (Osage University Partners), Topspin Partners and other 7 institutions followed up with US$62 million in funding.
- On August 3, 2020, in the D round of financing, PMV Pharmaceuticals received US$70 million in funding from 7 institutions including OrbiMed, RA Capital Management, Wellington Management, Viking Global Investors, and Boxer Capital.
PMV Pharmaceuticals (PMVP) investment:
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) was listed on NASDAQ on 9/25/2020 IPO, with an issue price of $18.00, issuing 7.4 million shares, raising US$133.2 million, underwriting by Goldman Sachs/ BofA Securities/ Cowen/ Evercore ISI .